Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average – Should You Sell?

Agenus Inc. (NASDAQ:AGEN)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.74 and traded as high as $4.55. Agenus shares last traded at $4.39, with a volume of 292,672 shares trading hands.

Wall Street Analysts Forecast Growth

AGEN has been the topic of several analyst reports. Zacks Research raised shares of Agenus to a “hold” rating in a report on Tuesday, August 12th. Robert W. Baird lifted their target price on shares of Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a report on Wednesday, June 4th. HC Wainwright raised shares of Agenus from a “neutral” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Wednesday, June 4th. Finally, Wall Street Zen downgraded shares of Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Agenus has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

Agenus Stock Down 2.9%

The stock has a market cap of $139.87 million, a PE ratio of -0.61 and a beta of 1.62. The business’s fifty day moving average is $5.29 and its 200 day moving average is $3.74.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million for the quarter, compared to analysts’ expectations of $49.71 million. As a group, analysts predict that Agenus Inc. will post -12.55 EPS for the current year.

Institutional Trading of Agenus

A number of institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its holdings in Agenus by 265.9% during the second quarter. Tower Research Capital LLC TRC now owns 21,871 shares of the biotechnology company’s stock worth $100,000 after buying an additional 15,893 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of Agenus in the second quarter valued at about $169,000. Engineers Gate Manager LP purchased a new stake in shares of Agenus in the second quarter valued at about $108,000. Brevan Howard Capital Management LP purchased a new stake in shares of Agenus in the second quarter valued at about $207,000. Finally, Bank of America Corp DE lifted its holdings in shares of Agenus by 110.0% in the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after purchasing an additional 220,327 shares in the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.